Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome (Nasdaq: IMNM) said members of management will present at two investor conferences on December 3, 2025. Presentations and times: Piper Sandler 37th Annual Healthcare Conference at 9:00 a.m. ET and Evercore 8th Annual Healthcare Conference at 9:10 a.m. ET. Interested parties can listen via live audio webcasts on the company’s Investor Relations website at www.immunome.com. Replay webcasts will be available for approximately 30 days after each live presentation.
Immunome (Nasdaq: IMNM) reported third quarter 2025 results and a program update on November 6, 2025. Cash and cash equivalents were $272.6 million as of September 30, 2025, including $44.9 million net proceeds from its at-the-market equity offering; the company expects this cash to fund operations into 2027.
Clinical highlights: topline data for the Phase 3 RINGSIDE Part B study of varegacestat is expected before end of 2025; objective responses were observed at multiple dose levels in B-cell lymphoma patients treated with IM-1021, with initial IM-1021 data planned for 2026. IND clearance for IM-3050 was received in April 2025.
Quarterly expenses included R&D of $49.2 million and G&A of $10.9 million; net loss was $57.5 million.
Immunome (Nasdaq: IMNM) announced that on Nov. 3, 2025 its Compensation Committee granted inducement stock options to three new employees under the company’s 2024 Inducement Plan.
The grants total 19,000 nonstatutory stock options with an exercise price of $17.00 per share (the company’s closing price on Nov. 3, 2025). The options vest over four years: 25% at the one-year anniversary of the vesting commencement date and the remainder vesting monthly over the following 36 months, subject to continued service, and are governed by the 2024 Inducement Plan and individual option agreements.
The Compensation Committee approved the awards as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ: IMNM) said management will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on Tuesday, Nov. 11, 2025 at 8:30 a.m. ET.
Investors can listen via a live audio webcast from the company Investor Relations website at www.immunome.com. A replay will be available for approximately 30 days after the live presentation.
Immunome (Nasdaq: IMNM) presented preclinical data on Oct. 23, 2025 showing its proprietary ADC payload HC74 overcomes several ADC resistance mechanisms, including payload efflux and target heterogeneity.
The poster reported HC74 is a novel topoisomerase I inhibitor used in IM-1021 (a ROR1-targeted ADC in Phase 1) and in multiple preclinical candidates; key findings include high membrane permeability, robust bystander activity, and efficacy in preclinical models refractory or resistant to trastuzumab-DXd, irinotecan, and models with heterogeneous target expression.
A copy of the poster is available in the company’s Events & Presentations materials.
Immunome (Nasdaq: IMNM) announced that on Oct. 1, 2025 its Compensation Committee granted inducement awards of 69,000 non‑statutory stock options to purchase common stock to five new employees under the 2024 Inducement Plan.
Each option has an exercise price of $11.34 equal to the Company’s closing price on Oct. 1, 2025, and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and the terms of the 2024 Inducement Plan and the applicable stock option agreements. The grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ:IMNM) has entered into a research collaboration agreement with Infinimmune for novel antibody discovery and optimization. The partnership leverages Infinimmune's GLIMPSE™ and Anthrobody® platforms to transform early-stage antibodies into development-ready therapeutic candidates.
Under the agreement, Immunome receives target exclusivity, with Infinimmune handling antibody discovery and optimization while Immunome will manage development and commercialization of resulting candidates. Financial terms were not disclosed.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants to new employees. The Compensation Committee approved non-statutory stock options for 117,000 shares of common stock to 8 new employees under the company's 2024 Inducement Plan.
The stock options have an exercise price of $9.28 per share, based on the company's closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Immunome (NASDAQ:IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 1:00 p.m. Eastern Time.
Investors and interested parties can access the presentation through a live audio webcast available on the Investor Relations section of Immunome's website. The presentation recording will remain accessible for approximately 30 days following the live event.
Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, reported its Q2 2025 financial results and pipeline updates. The company's cash position of $268.0 million is expected to fund operations into 2027.
Key pipeline developments include: varegacestat's upcoming Phase 3 RINGSIDE topline data expected by end of 2025 and recent European Medicines Agency Orphan Drug Designation; IM-1021's ongoing Phase 1 trial reaching its third dose level; and IM-3050's IND clearance with Phase 1 trial initiation planned for late 2025. Three additional preclinical ADCs (IM-1617, IM-1340, and IM-1335) are undergoing IND-enabling work.
Q2 2025 financials showed R&D expenses of $40.5 million and G&A expenses of $10.0 million, with a net loss of $43.4 million.